12,960 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by Legato Capital Management LLC

Legato Capital Management LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,960 shares of the company’s stock, valued at approximately $305,000.

A number of other institutional investors also recently bought and sold shares of DYN. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE lifted its stake in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at approximately $62,000. Finally, KBC Group NV grew its position in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Down 1.0 %

Shares of DYN opened at $13.91 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $13.07 and a twelve month high of $47.45. The firm has a market capitalization of $1.42 billion, a P/E ratio of -3.91 and a beta of 1.11. The firm’s 50-day moving average is $19.45 and its two-hundred day moving average is $29.73.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,289 shares of company stock valued at $580,592. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Finally, JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.